Barclays analyst Peter Lawson has significantly reduced the price target for Arcus Biosciences (RCUS, Financial), bringing it down to $14 from the previous target of $29. Despite this adjustment, Lawson maintains an Overweight rating on the stock. The decision to cut the target comes as a result of the firm "derisking" the company's model, reflecting a more cautious outlook on the stock's future performance.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 11 analysts, the average target price for Arcus Biosciences Inc (RCUS, Financial) is $31.73 with a high estimate of $46.00 and a low estimate of $15.00. The average target implies an upside of 292.18% from the current price of $8.09. More detailed estimate data can be found on the Arcus Biosciences Inc (RCUS) Forecast page.
Based on the consensus recommendation from 13 brokerage firms, Arcus Biosciences Inc's (RCUS, Financial) average brokerage recommendation is currently 1.9, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Arcus Biosciences Inc (RCUS, Financial) in one year is $10.97, suggesting a upside of 35.6% from the current price of $8.09. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Arcus Biosciences Inc (RCUS) Summary page.
